KAHR Medical Raises $18 Million in Private Funding Round
Funds will be used for advancing the Company’s next generation immuno-oncology drug candidates, including lead anti-CD47 product for the treatment of solid tumors through Phase I/II study in addition to advancing preclinical pipeline
Kahr raises $18M to test CD47 drug with Roche’s Tecentriq
Kahr Medical has raised $18 million (€17 million) to take an anti-CD47 drug into the clinic. The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test as a single agent and in combination with Roche’s checkpoint inhibitor Tecentriq.
Cancer treatment co Kahr Medical raises $18m
The round was led by Flerie Invest AB, Oriella Limited, Hadasit Bio-Holdings, Pavilion Capital, and Mirae Asset Venture Investment.
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients
KAHR Medical, a biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as DSP (Dual Signaling Proteins), announced today a new clinical collaboration with Roche.
Startup joins Roche to hold clinical trials for double-whammy cancer drug
KAHR Medical, an Israeli biopharmaceutical company, says it is developing a second generation class of immunotherapy drugs that it hopes will be more effective in tackling cancer, based on the lessons learned from drugs that are already in use.